149 related articles for article (PubMed ID: 2142026)
1. Potency and selectivity of the non-steroidal aromatase inhibitor CGS 16949A in postmenopausal breast cancer patients.
Dowsett M; Stein RC; Mehta A; Coombes RC
Clin Endocrinol (Oxf); 1990 May; 32(5):623-34. PubMed ID: 2142026
[TBL] [Abstract][Full Text] [Related]
2. Specificity of low dose fadrozole hydrochloride (CGS 16949A) as an aromatase inhibitor.
Santen RJ; Demers LM; Lynch J; Harvey H; Lipton A; Mulagha M; Hanagan J; Garber JE; Henderson IC; Navari RM
J Clin Endocrinol Metab; 1991 Jul; 73(1):99-106. PubMed ID: 1646219
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of aromatase with CGS 16949A in postmenopausal women.
Santen RJ; Demers LM; Adlercreutz H; Harvey H; Santner S; Sanders S; Lipton A
J Clin Endocrinol Metab; 1989 Jan; 68(1):99-106. PubMed ID: 2521224
[TBL] [Abstract][Full Text] [Related]
4. Preliminary study of the treatment of advanced breast cancer in postmenopausal women with the aromatase inhibitor CGS 16949A.
Stein RC; Dowsett M; Davenport J; Hedley A; Ford HT; Gazet JC; Coombes RC
Cancer Res; 1990 Mar; 50(5):1381-4. PubMed ID: 2137367
[TBL] [Abstract][Full Text] [Related]
5. A phase I trial of CGS 16949A. A new aromatase inhibitor.
Lipton A; Harvey HA; Demers LM; Hanagan JR; Mulagha MT; Kochak GM; Fitzsimmons S; Sanders SI; Santen RJ
Cancer; 1990 Mar; 65(6):1279-85. PubMed ID: 2137721
[TBL] [Abstract][Full Text] [Related]
6. The influence of CGS 16949A on peripheral aromatisation in breast cancer patients.
Lønning PE; Jacobs S; Jones A; Haynes B; Powles T; Dowsett M
Br J Cancer; 1991 May; 63(5):789-93. PubMed ID: 1828173
[TBL] [Abstract][Full Text] [Related]
7. Effects of Fadrozole (CGS 16949A) and Letrozole (CGS 20267) on the inhibition of aromatase activity in breast cancer patients.
Demers LM
Breast Cancer Res Treat; 1994; 30(1):95-102. PubMed ID: 7949208
[TBL] [Abstract][Full Text] [Related]
8. Effect of CGS 16949A plus tamoxifen on induced mammary tumours in rats.
Tominaga T; Yoshida Y; Shimozuma K; Hayashi K; Kosaki G
Eur J Cancer; 1990; 26(5):600-3. PubMed ID: 2144748
[TBL] [Abstract][Full Text] [Related]
9. The effects of CGS 16949A, an aromatase inhibitor on adrenal mineralocorticoid biosynthesis.
Demers LM; Melby JC; Wilson TE; Lipton A; Harvey HA; Santen RJ
J Clin Endocrinol Metab; 1990 Apr; 70(4):1162-6. PubMed ID: 2156889
[TBL] [Abstract][Full Text] [Related]
10. Highly selective inhibition of estrogen biosynthesis by CGS 20267, a new non-steroidal aromatase inhibitor.
Bhatnagar AS; Häusler A; Schieweck K; Lang M; Bowman R
J Steroid Biochem Mol Biol; 1990 Dec; 37(6):1021-7. PubMed ID: 2149502
[TBL] [Abstract][Full Text] [Related]
11. The new aromatase inhibitor CGS-16949A suppresses aldosterone and cortisol production by human adrenal cells in vitro.
Lamberts SW; Bruining HA; Marzouk H; Zuiderwijk J; Uitterlinden P; Blijd JJ; Hackeng WH; De Jong FH
J Clin Endocrinol Metab; 1989 Oct; 69(4):896-901. PubMed ID: 2550511
[TBL] [Abstract][Full Text] [Related]
12. A study of fadrozole, a new aromatase inhibitor, in postmenopausal women with advanced metastatic breast cancer.
Raats JI; Falkson G; Falkson HC
J Clin Oncol; 1992 Jan; 10(1):111-6. PubMed ID: 1530798
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo studies demonstrating potent and selective estrogen inhibition with the nonsteroidal aromatase inhibitor CGS 16949A.
Steele RE; Mellor LB; Sawyer WK; Wasvary JM; Browne LJ
Steroids; 1987; 50(1-3):147-61. PubMed ID: 2973160
[TBL] [Abstract][Full Text] [Related]
14. An in vitro method to determine the selective inhibition of estrogen biosynthesis by aromatase inhibitors.
Häusler A; Schenkel L; Krähenbühl C; Monnet G; Bhatnagar AS
J Steroid Biochem; 1989 Jul; 33(1):125-31. PubMed ID: 2527324
[TBL] [Abstract][Full Text] [Related]
15. Effect of the potent aromatase inhibitor fadrozole hydrochloride (CGS 16949A) in postmenopausal women with breast carcinoma.
Costa LA; Kopreski MS; Demers LM; Chinchilli VM; Santen RJ; Harvey HA; Lipton A
Cancer; 1999 Jan; 85(1):100-3. PubMed ID: 9921980
[TBL] [Abstract][Full Text] [Related]
16. Endocrine, pharmacokinetic and clinical studies of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione ('pyridoglutethimide') in postmenopausal breast cancer patients.
Dowsett M; MacNeill F; Mehta A; Newton C; Haynes B; Jones A; Jarman M; Lonning P; Powles TJ; Coombes RC
Br J Cancer; 1991 Nov; 64(5):887-94. PubMed ID: 1931611
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in healthy postmenopausal women.
Iveson TJ; Smith IE; Ahern J; Smithers DA; Trunet PF; Dowsett M
J Clin Endocrinol Metab; 1993 Aug; 77(2):324-31. PubMed ID: 8345035
[TBL] [Abstract][Full Text] [Related]
18. Endocrine changes with the aromatase inhibitor fadrozole hydrochloride in breast cancer.
Dowsett M; Smithers D; Moore J; Trunet PF; Coombes RC; Powles TJ; Rubens R; Smith IE
Eur J Cancer; 1994; 30A(10):1453-8. PubMed ID: 7833101
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of estrogen biosynthesis and its consequences on gonadotrophin secretion in the male.
Bhatnagar AS; Müller P; Schenkel L; Trunet PF; Beh I; Schieweck K
J Steroid Biochem Mol Biol; 1992 Mar; 41(3-8):437-43. PubMed ID: 1532903
[TBL] [Abstract][Full Text] [Related]
20. CGS 16949A, a new aromatase inhibitor in the treatment of breast cancer--a phase I study.
Beretta KR; Hoeffken K; Kvinnsland S; Trunet P; Chaudri HA; Bhatnagar AS; Goldhirsch A; Cavalli F
Ann Oncol; 1990 Nov; 1(6):421-6. PubMed ID: 2150591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
